NASDAQ: BRNS - Barinthus Biotherapeutics plc

半年間の収益性: -26.06%
配当利回り: 0.00%

プロモーションスケジュール Barinthus Biotherapeutics plc


会社について Barinthus Biotherapeutics plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

さらに詳しく
The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

IPO date 2021-04-30
ISIN US91864C1071
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.barinthusbio.com
Цена ао 2.4
1日あたりの価格変動: 0% (1.06)
週ごとの価格変動: -4.5% (1.11)
月ごとの料金変更: +11.02% (0.9548)
3ヶ月間の価格変動: -10.18% (1.1801)
半年間の価格変動: -26.06% (1.4336)
年間の価格変動: -71.27% (3.69)
3年間の価格推移: -88.38% (9.12)
5年間の価格推移: 0% (1.06)
10年間の価格推移: 0% (1.06)
年初からの価格変動: -22.82% (1.3734)

過小評価

名前 意味 学年
P/S 167.83 1
P/BV 0.7226 10
P/E 0 0
EV/EBITDA -0.0845 0
合計: 5.13

効率

名前 意味 学年
ROA, % -34.33 0
ROE, % -39.42 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.1826 10
合計: 9.4

成長の衝動

名前 意味 学年
収益性 Revenue, % -88.38 0
収益性 Ebitda, % 179.78 10
収益性 EPS, % 212.67 10
合計: 8

スーパーバイザー 役職 支払い 生年
Mr. William J. Enright MBA CEO & Director 969.44k 1962 (63 年)
Ms. Sarah Gilbert Co-Founder 48.98k
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor 61.61k
Ms. Gemma Brown CFO & Company Secretary N/A 1991 (34 年)
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 593.48k 1979 (46 年)
Mr. Graham Griffiths Chief Operating Officer 522.23k 1979 (46 年)
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations N/A
Bernie McDonald Head of IP N/A
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies N/A
Dr. Leon Hooftman M.D. Chief Medical Officer

住所: United Kingdom, Harwell OX DF, Zeus Building - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.barinthusbio.com